ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Mechanism of anti-hyperuricemia of isobavachin based on network pharmacology and molecular docking

Luo, Jia-jun; Chen, Xin-hua; Liang, Peng-ying; Zhao, Zean; Wu, Ting; Li, Zhong-huang; Wan, Shan-he; Luo, Jian; Pang, Jian-xin*; Zhang, Jia-jie*; Tian, Yuan-xin*南方医科大学
Computers in Biology and Medicine2023-3DOI: 10.1016/j.compbiomed.2023.106637
23阅读
引用收藏
分享

摘要

Background: Hyperuricemia is a more popular metabolic disease caused by a disorder of purine metabolism. Our previous study firstly screened out a natural product Isobavachin as anti-hyperuricemia targeted hURAT1 from a Chinese medicine Haitongpi (Cortex Erythrinae). In view of Isobavachin's diverse pharmacological activities, similar to the Tranilast (as another hURAT1 inhibitor), our study focused on its potential targets and molecular mechanisms of Isobavachin anti-hyperuricemia based on network pharmacology and molecular docking.Methods: First of all, the putative target genes of compounds were screen out based on the public databases with different methods, such as SwissTargetPerdiction, PharmMapper and TargetNet,etc. Then the compoundpathways were obtained by the compounds' targets gene from David database for Gene Ontology (GO) function enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enrichment analysis. The cross pathways of compound-pathways and the diseases pathways of hyperuricemia from Comparative Toxicogenomics Database were be considered as the compound-disease pathways. Next, based on the compounddisease pathways and the PPI network, the core targets were identified based on the retrieved disease-genes. Finally, the compound-target-pathway-disease network was constructed by Cytoscape and the mechanism of isobavachin anti-hyperuricemia was discussed based on the network analysis.Results: Our study demonstrated that there were five pathways involved in Isobavachin against hyperuricemia, including Drug metabolism-other enzymes, Metabolic pathways, Bile secretion, Renin-angiotensin system and Renin secretion. Among the proteins involved in these pathways, HPRT1, REN and ABCG2 were identified as the core targets associated with hyperuricemia, which regulated the five pathways mentioned above. It is quite different from that of Tranilast, which involved in the same pathways except Bile secretion instead of purine metabolism.Conclusion: This study revealed Isobavachin could regulate the pathways including Drug metabolism-other enzymes, Metabolic pathways, Bile secretion, Renin-angiotensin system, Renin secretion by core targets HPRT1, REN and ABCG2, in the treatment of hyperuricemia effect. Among them, the Bile secretion regulated by ABCG2 probably would be a novel pathway. Our work provided a theoretical basis for the pharmacological study of Isobavachin in lowering uric acid and further basic research.

学科与关键词

关键词
IsobavachinHyperuricemiaNetwork pharmacologyTranilastMolecular mechanism
相关
加载中…
  • Pharmacological evaluation of a novel skeleton compound isobavachin (4?,7-dihydroxy-8-prenylflavanone) as a hypouricemic agent: Dual actions of URAT1/GLUT9 and xanthine oxidase inhibitory activity
    Zhao, Zean; Luo, Jian; Liao, Hui; Zheng, Fengxin; Chen, Xinhua; Luo, Jiajun; Chen, Yongjun; Zhao, Kunlu; Zhang, Shuqin; Tian, Jinhong; Wu, Ting; Li, Yongmei; Li, Lu; Yang, Yang; Lin, Cuiting; Zhang, Qun*; Tian, Yuanxin*; Pang, Jianxin*Bioorganic Chemistry, 2023, 133: 106405.被引 2
  • Novel natural scaffold as hURAT1 inhibitor identified by 3D-shape-based, docking-based virtual screening approach and biological evaluation
    Chen, Xinhua; Zhao, Zean; Luo, Jiajun; Wu, Ting; Shen, Yudong; Chang, Shan; Wan, Shanhe; Li, Zhonghuang; Zhang, Jiajie*; Pang, Jianxin*; Tian, Yuanxin*Bioorganic Chemistry, 2021, 117: 105444.被引 6
  • Integrating multi-level interactive network and in vivo/vitro studies to explore the protective mechanism of Ampelopsis grossedentata in hyperuricemia
    Zhou, Qi-Xiu; Zhou, Qian; Zhang, Peng; Xie, Yan-Qing; Yang, Zhu-Ya; Tan, Wen-Hong; Khan, Afsar; Duan, Wei-Gang; Zhou, Zhi-Hong; Liu, Lu*FITOTERAPIA, 2024, 172: 105718.
查看全部 →

发表信息

论文状态
公开发表
期刊
Computers in Biology and Medicine
发表日期
2023-03
卷期
第 155 卷
页码
106637
DOI
10.1016/j.compbiomed.2023.106637
语言
ENGLISH
成果收录
SCIE
资助标注
National Foundation Science of China [81974507]; Science and Technology Project of Guangzhou, China [202201010844]

作者

  • L

    Luo, Jia-jun (第一作者)

  • C

    Chen, Xin-hua

    new · southern med univ

查看全部 11 位作者收起作者
  • L

    Liang, Peng-ying

    new · southern med univ

  • Z

    Zhao, Zean

    new · southern med univ

  • W

    Wu, Ting

    new · southern med univ

  • L

    Li, Zhong-huang

    new · southern med univ

  • W

    Wan, Shan-he

    new · southern med univ

  • L

    Luo, Jian

  • P

    Pang, Jian-xin (通讯)

    new · southern med univ

  • Z

    Zhang, Jia-jie (通讯)

    new · southern med univ

  • T

    Tian, Yuan-xin (通讯)

    new · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417